Diagonal Therapeutics
Diagonal Therapeutics Raises $125M Series B | Antibody Therapeutics
Diagonal Therapeutics Closes $125M Series B
Diagonal Therapeutics, developing disease-modifying clustering antibodies for rare genetic diseases, has raised $125 million in Series B funding.
The round was led by Sanofi Ventures and Janus Henderson Investors.
Key Highlights
- Focus on rare genetic diseases
- Novel antibody platform
- Strategic pharma backing from Sanofi
Company Overview
Diagonal Therapeutics is pioneering a new class of therapeutics using clustering antibodies to address rare genetic diseases with high unmet medical need.
Company Info
Investors (2)
Share
Related Reports
Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform
Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.
Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation
French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free